Search Protocols under revision. Back New search Go to resultsDiseaseMain groupCross-Sectional, Transplantation, Cellular TherapySolid TumorsProtocol groupGynecological OncologyradiotherapySarcomasDiseaseEndometrial CancerSubgroupHR+ postmenopausalMismatch Repair - deficient / Microsatellite Instability - high (dMMR/MSI-H)ICD10C54.1MeSHCarcinosarcomaEndometrial NeoplasmsSequenceAtTEnd: ATEZ1200/PACL175/CRBP5, Endometrial Ca, C1-8 (PID2698) -|- ATEZ1200, C9+ (PID2699)DOXO60/CISP50, Endometrial Ca, C1-7 (PID894) -|- CISP50, C8 (PID895)DUO-E: DURV1120/PACL175/CRBP5, Endometrial Ca (PID2816) -|- DURV1500/OLAP300, maint. (pMMR) (PID2817) or DURV1500, maint. (dMMR) (PID2818)ENGOT-en11/GOG-3053/KEYNOTE-B21 (alternative with Docetaxel): PEMB200/DOCE75/CRBP6, Endometrial Ca, adj., C1-6 (PID2752) or PEMB200/DOCE25/CRBP2, Endometrial Ca, adj., C1-6 (PID2753) -|- (PID2736) -|- C7-12 (PID2738)ENGOT-en11/GOG-3053/KEYNOTE-B21: PEMB200/PACL175/CRBP6, Endometrial Ca, adj., C1-6 (PID2737) or PEMB200/PACL60/CRBP2, Endometrial Ca, adj., C1-6 (PID2739) -|- (PID2736) -|- C7-12 (PID2738)GARNET: DOST500, Endometrial Ca, C1-4 (PID1797) -|- DOST1000, C5+ (PID1798)NRG-GY018 / Keynote-868: PEMB200/PACL175/CRBP5, Endometrial Ca, C1-6 (PID2315) -|- PEMB400, C7-20 (PID2316)PORTEC-3: CISP50/Radiation, Endometrial Ca, adj. A (PID922) -|- PACL175/CRBP5, adj, B (PID923)RUBY: DOST500/PACL175/CRBP5, Endometrial Ca, C1-6 (PID2313) -|- DOST1000, C7+ (PID2314)TRAS8/PACL175/CRPB5, Endometrial Ca, C1 (PID2215) -|- C2-6 (PID2216) -|- C7+ (PID2217)ChemotherapyChemo-substanceAnastrozoleAtezolizumabAvelumabBevacizumabCarboplatinCisplatinDocetaxelDostarlimabDoxorubicinDurvalumabEverolimusIfosfamideLenvatinibLetrozoleMegestrolOlaparibPaclitaxelPembrolizumabSacituzumab GovitecanTalazoparibTopotecanTrastuzumabChemo-substanceAnastrozoleAtezolizumabAvelumabBevacizumabCarboplatinCisplatinDocetaxelDostarlimabDoxorubicinDurvalumabEverolimusIfosfamideLenvatinibLetrozoleMegestrolOlaparibPaclitaxelPembrolizumabSacituzumab GovitecanTalazoparibTopotecanTrastuzumabChemo-substanceAnastrozoleAtezolizumabAvelumabBevacizumabCarboplatinCisplatinDocetaxelDostarlimabDoxorubicinDurvalumabEverolimusIfosfamideLenvatinibLetrozoleMegestrolOlaparibPaclitaxelPembrolizumabSacituzumab GovitecanTalazoparibTopotecanTrastuzumabChemo-substanceAnastrozoleAtezolizumabAvelumabBevacizumabCarboplatinCisplatinDocetaxelDostarlimabDoxorubicinDurvalumabEverolimusIfosfamideLenvatinibLetrozoleMegestrolOlaparibPaclitaxelPembrolizumabSacituzumab GovitecanTalazoparibTopotecanTrastuzumabNo. Substances123 RadiotherapySupportive therapySupportive substanceBalanced Crystalloid SolutionCimetidineDexamethasoneDimetindenFosaprepitantGranisetronMagnesiumMagnesium sulfateMesnaParacetamolPegfilgrastimPotassium chlorideSupportive substanceBalanced Crystalloid SolutionCimetidineDexamethasoneDimetindenFosaprepitantGranisetronMagnesiumMagnesium sulfateMesnaParacetamolPegfilgrastimPotassium chlorideSupportive substanceBalanced Crystalloid SolutionCimetidineDexamethasoneDimetindenFosaprepitantGranisetronMagnesiumMagnesium sulfateMesnaParacetamolPegfilgrastimPotassium chlorideSupportive substanceBalanced Crystalloid SolutionCimetidineDexamethasoneDimetindenFosaprepitantGranisetronMagnesiumMagnesium sulfateMesnaParacetamolPegfilgrastimPotassium chlorideNo. Substances12345678Protocol classificationTherapy classificationalternativecurrent standardIntensityStandard doseTherapy indicationFirst lineRelapse therapySecond lineseveral possibleTherapy phaseMaintenanceTherapy intentioncurativepalliativeRisksAdrenal InsufficiencyAlopeciaAnemia Hb below 8g/dlAnemia Hb below 10g/dlAnorexiaArthalgiaAstheniaCardiotoxicityColitisConstipationDiarrheaDyspneaEdemaEmetogenicity (ASCO)Emetogenicity (MASCC/ESMO)FatigueFebrile NeutropeniaGastrointestinal ToxicityHand-Foot SyndromeHeadacheHepatotoxicityHyperglycemiaHypertensionHyperthyroidismHypertriglyceridemiaHypokalemiaHypophysitisHypothyroidismIncrease AminotransferasesInfectionsInfusion ReactionLeukopeniaMucositisNauseaNeuropathyNeurotoxicityNeutropeniaOral MucositisPainPancreatitisPneumonitisProteinuriaPruritusPyrexiaRashRenal FailureSepsisThrombocytopenia below 50 000/µlThromboembolic Event only studiesPublicationAuthorAghajanian CColombo N De Boer SDenschlag DEskander RNFader ANHomesley HKonstantinopoulos PALissoni AMakker VMatei DMileshkin LMiller DSMirza MROaknin AO´Malley DPandya KJRandall MSantin ADSlomovitz BSorbe, BVan Gorp TWadler SWestin SWolfson AHDiseaseEndometrium-Ca, Stadium III-IV, adjuvant und nach Strahlentherapie, ECOG 0-2Endometriumkarzinom, adeno- oder plattenepithel-adeno, Zweitlinie, ECOG >1Endometriumkarzinom, FIGO III-IVA, ECOG 0-2, ErstlinientherapieEndometriumkarzinom, lokal fortgeschritten, nicht operabel oder metastasiert, FIGO III oder IV, ECOG 0-1Endometriumkarzinom, lokal fortgeschritten, nicht operabel oder metastasiert, FIGO III oder IV, ECOG 0-2Endometriumkarzinom, nach Versagen einer vorangegangenen hormonellen oder BestrahlungstherapieEndometriumkarzinom, Stadium I-III, postoperativ, ECOG 0-2Endometriumkarzinom, Stadium III-IV, nicht operabel, ECOG 0-2, ErstlinieEndometriumkarzinom oder Karzinosarkom, lokal fortgeschritten, nicht operabel/ metastasiert, FIGO III/IV, ECOG 0-2Endometriumkarzinom oder Karzinosarkom, neu diagnostiziert, operabel, Hochrisiko (FIGO I/II mit TP53+ oder FIGO III/IV), ECOG 0-1Endometriumkarzinom Stadium III-IV, ECOG 0-3fortgeschr. rezidiv. Endometriumkarzinomfortgeschrittenes Endometriumkarzinom, metastasiertes, nichtresezierbares -, MSI-H/dMMR, ECOG 0-1fortgeschrittenes oder rezidiviertes Endometriumkarzinom, 0-2 Vortherapien, ECOG 0-2Karzinosarkom des Endometriums, FIGO I-IVB Karzinosarkom des Uterus, FIGO-Stadium I-IVMetastasiertes Endometriumkarzinom, Progress nach platinhaltiger und Checkpoint-Inhibitor-Therapiemetastasiertes Endometriumkarzinom, Zweit- oder Drittlinie, ECOG 0-1Metastasiertes oder lokal fortgeschrittenes rezidiviertes Endometriumkarzinom, ohne vorherige antihormonelle Behandlung, ER und /oder PR positiv, EGOG 0-2Metastasiertes oder lokal fortgeschrittenes rezidiviertes Endometriumkarzinom, ohne vorherige antihormonelle Behandlung, GOG 0-2neu diagnostiziertes oder rezidiviertes Endometriumkarzinom, Stadium III/IV, ECOG 0-1refraktäres oder wiederkehrendes Karzinosarkom des Uterus, Stadium III - IV, ECOG 0-2rezidivierendes Endometriumkarzinom, 1-2 vorangegangene Therapien, GOG 0-2Rezidiviertes Endometriumkarzinom, mismatch repair proficient (MMRP)rezidiviertes oder fortgeschritten Endometriumkarzinom, dMMR/MSI-H, nach platinbasierter TherapieSeröses Endometrium-Ca, lokal fortgeschritten oder rezidiviert, FIGO III-IV, Her2/neu-Überexpression, ECOG 0-2 OriginBrody School of Medicine, Division of Gynecologic Oncology, Leo Jenkins Cancer Center, Greenville, GOGCopenhagen University Hospital, and the Nordic Society of Gynaecological Oncology-Clinical Trial Unit, Copenhagen, RUBY trialDana-Farber Cancer Institute, Boston, MassachusettsDepartment of Gynecological Oncology, University Hospital, Orebro, SchwedenDepartment of Gynecology, Hochtaunuskliniken Bad Homburg, Bad Homburg, GermanyDepartment of Obstetrics and Gynecology, Division of Gynecologic Oncology, NC, A Gynecologic Oncology Group StudyDepartment of Obstetrics and Gynecology, S. Gerardo Hospital, University of Milan, Monza, ItalyDepartment of Radiation Oncology, Leiden University Medical Center, Netherlands PORTEC-3Eastern Cooperative Oncology Group, Studie E3E93European Institute of Oncology IRCCS, Milan, Italy, AtTEnd trialJohn Hopkins School of Medicine, Baltimore, MarylandLeo W. Jenkins Cancer Center, Brody School of Medicine at East Carolina University, Greenville, GOGMemorial Sloan-Kettering Cancer Center, New York, Gynecologic Oncology GroupMemorial Sloan Kettering Cancer Center, New York, NY, USA, Keynote-775Northwestern University, Chicago, USASylvester Cancer Center, University of Miami Miller School of Medicine, Miami, USASylvester Comprehensive Cancer Center, University of Miami and The University of Texas MD Anderson Cancer CenterThe Ohio State University Wexner Medical Center and The James Comprehensive Cancer Center, Ohio, KEYNOTE-158The University of Melbourne, Melbourne, Australia, The PARAGON trial – ANZGOG 0903University Hospital Leuven, Leuven Cancer Institute, Leuven, Belgium, ENGOT-en11/GOG-3053/KEYNOTE-B21 TrialUniversity of California, San Diego, Rebecca and John Moores Cancer Center, La Jolla, NRG-GY018 trial, Keynote-868 University of California, San Diego, Rebecca and John Moores Cancer Center, La Jolla, NRG-GY018 trial, Keynote-868 University of Rochester Cancer Center, New York, Eastern Cooperative Oncology Group StudyUniversity of Texas MD Anderson Cancer Center, Houston, TX, DUO-E TrialUniversity of Texas Southwestern Medical Center, Dallas, USA, NRG Oncology, GOG0209Vall d'Hebron University Hospital, Barcelona, SpainYale School of Medicine, New Haven, CT, TROPiCS-03 trialProtocols in Revision 41 protocols foundAnastrozole 1, Endometrial Cancer (PID2199 V1.0)Atezolizumab 1200 / Paclitaxel 175 / Carboplatin 5 - Atezolizumab 1200, Endometrial Cancer, Cycle 9+ (PID2699 V1.0)Atezolizumab 1200 / Paclitaxel 175 / Carboplatin 5, Endometrial Cancer, Cycle 1-8 (PID2698 V1.0)Avelumab 800 / Talazoparib 1, Endometrial Cancer (PID2173 V1.0)Bevacizumab 15, Endometrial Cancer (PID896 V1.0)Cisplatin 50 / Radiation, Endometrial Cancer adjuvant, Part A (PID922 V1.1)Dostarlimab 1000, Endometrial Cancer, Cycle 5+ (PID1798 V1.0)Dostarlimab 500 / Paclitaxel 175 / Carboplatin 5 - Dostarlimab 1000, Endometrial Cancer, Cycle 7+ (PID2314 V1.0)Dostarlimab 500 / Paclitaxel 175 / Carboplatin 5, Endometrial Cancer, Cycle 1-6 (PID2313 V1.0)Dostarlimab 500, Endometrial Cancer, Cycle 1-4 (PID1797 V1.0)Doxorubicin 45 / Cisplatin 50, Endometrial Cancer, Adjuvant (PID893 V1.1)Doxorubicin 60 / Cisplatin 50 - Cisplatin 50, Endometrial Cancer, Cycle 8 (PID895 V1.1)Doxorubicin 60 / Cisplatin 50, Endometrial Cancer, Cycle 1-7 (PID894 V1.1)Durvalumab 1120 / Paclitaxel 175 / Carboplatin 5, Endometrial Cancer (PID2816 V1.0)Durvalumab 1500 / Olaparib 300, Endometrial Cancer, maintenance (PID2817 V1.0)Durvalumab 1500, Endometrial Cancer, maintenance (PID2818 V1.0)Everolimus 10 / Letrozole 2.5, Endometrial Cancer (PID897 V1.0)Ifosfamide 1.5 / Cisplatin 20, Uterine Carcinosarcoma, adjuvant (PID1584 V1.1)Lenvatinib 20 / Pembrolizumab 200, Endometrial Cancer (PID590 V1.0)Megestrol 160, Endometrial Cancer (PID2198 V1.0)Paclitaxel 135 / Ifosfamide 1.6, Uterine Carcinosarcoma (PID1110 V1.0)Paclitaxel 175 / Carboplatin 5, Endometrial Cancer (PID124 V1.2)Paclitaxel 175 / Carboplatin 5, Endometrial Cancer adjuvant, Part B (PID923 V1.1)Paclitaxel 175 / Carboplatin 5, Uterine Carcinosarcoma, adjuvant (PID1600 V1.0)Paclitaxel 175 / Carboplatin 6, Endometrial Cancer (PID1703 V1.0)Paclitaxel 175 / Carboplatin 6, Endometrial Cancer adjuvant (PID1579 V1.0)Paclitaxel 175, Endometrial Cancer (PID732 V1.1)Pembrolizumab 200 / Cisplatin 50 / Radiation, adjuvant, Endometrial Cancer (PID2736 V1.0)Pembrolizumab 200 / Docetaxel 25 / Carboplatin 2, Endometrial Cancer, adjuvant, cycle 1-6 (PID2753 V1.0)Pembrolizumab 200 / Docetaxel 75 / Carboplatin 6, Endometrial Cancer, adjuvant, cycle 1-6 (PID2752 V1.0)Pembrolizumab 200 / Paclitaxel 175 / Carboplatin 5 - Pembrolizumab 400, Endometrial Cancer, Cycle 7-20 (PID2316 V1.0)Pembrolizumab 200 / Paclitaxel 175 / Carboplatin 5, Endometrial Cancer, Cycle 1-6 (PID2315 V1.0)Pembrolizumab 200 / Paclitaxel 175 / Carboplatin 6, Endometrial Cancer, adjuvant, cycle 1-6 (PID2737 V1.0)Pembrolizumab 200 / Paclitaxel 60 / Carboplatin 2, Endometrial Cancer, adjuvant, cycle 1-6 (PID2739 V1.0)Pembrolizumab 200, Endometrial Cancer (PID1960 V1.0)Pembrolizumab 400, Endometrial Cancer, adjuvant, cycle 7-12 (PID2738 V1.0)Sacituzumab Govitecan 10, Endometrial Cancer (PID2828 V1.0)Topotecan 0.8, Endometrial Cancer (PID141 V2.0)Trastuzumab 6 / Paclitaxel 175 / Carboplatin 5, Endometrial Cancer, Cycle 2-6 (PID2216 V1.0)Trastuzumab 6, Endometrial Cancer, Cycle 7+ (PID2217 V1.0)Trastuzumab 8 / Paclitaxel 175 / Carboplatin 5, Endometrial Cancer, Cycle 1 (PID2215 V1.0)
